How Long Does It Take for Tamoxifen to Get Out of Your System?

After you stop taking tamoxifen, it takes roughly three weeks for about 98 percent of the drug to clear from your bloodstream. That estimate comes from tamoxifen’s elimination half-life, which ranges from about five to fourteen days depending on how long you have been taking it. But “out of your system” is more nuanced than a single number, because tamoxifen spreads deeply into body tissues, produces active metabolites that linger on their own schedules, and clears at different rates depending on your age, genetics, and other medications.

Why the Half-Life Is Longer Than You Might Expect

Tamoxifen follows what pharmacologists call a biphasic elimination pattern: blood levels drop fairly quickly at first, then taper off much more slowly in a second phase. The initial rapid decline reflects the drug leaving the bloodstream and settling into tissues, while the slower tail represents the drug gradually being metabolized and excreted. Clinical data show that after chronic dosing, the terminal half-life is around seven days, though estimates in the literature range from five to fourteen days depending on the study population and how half-life was measured.¹ By contrast, after a single first dose, the half-life is much shorter, roughly nine to twelve hours, because the drug has not yet accumulated in tissues.²

The reason for this difference is tamoxifen’s enormous volume of distribution. Pharmacokinetic modeling puts it somewhere around 700 to 1,400 liters, far more than your actual blood volume, which tells you the drug is heavily concentrated in fat, liver, lung, and other tissues rather than floating freely in the bloodstream.³ Those tissue stores slowly release tamoxifen back into circulation, which is why the tail end of elimination takes so long. Think of it like wringing out a very thick sponge: the first squeeze gets a lot of water out fast, but the last bit drips out slowly.

How the Body Gets Rid of Tamoxifen

Tamoxifen is primarily processed by enzymes in the liver and then excreted through bile into the gut. About 65 percent of an administered dose leaves the body in feces over a two-week period.¹ Urinary excretion plays a smaller role. One study looking at a specific tamoxifen metabolite in urine found it detectable for up to about five days after an oral dose.⁴

An interesting wrinkle is that the body appears to get better at excreting tamoxifen through bile the longer you take it. Animal research found that prior tamoxifen exposure increased biliary excretion of the drug and its metabolites substantially, from about 8 percent to roughly 51 percent of an administered dose, apparently driven by upregulation of a drug-transport protein in the liver.⁵ That adaptation may partly explain why some people seem to clear the drug somewhat more efficiently after long courses of treatment, though the clinical significance in humans is not fully pinned down.

Single Dose Versus Years of Treatment

If you have only taken one or two doses of tamoxifen, the drug will leave your system much faster than the three-week figure. That estimate applies to someone who has been on tamoxifen long enough to reach steady state, the point where the amount going in each day roughly equals the amount being eliminated. Reaching that steady state takes a surprisingly long time: around 16 weeks of daily dosing.² At that point, blood levels are about ten times higher than those seen after a single dose, because the drug has saturated its tissue compartments.

This matters practically. If you missed a few pills and are wondering whether the drug is gone, it almost certainly is not. Even a brief gap in dosing barely dents steady-state levels, because so much tamoxifen is stored in tissue. Conversely, if you took one dose and had a reaction, you can expect the drug to clear considerably faster than three weeks because it never had time to build up. The rule of thumb that it takes roughly five half-lives to eliminate a drug still applies, but you have to use the correct half-life for your situation: about half a day for a first dose, versus a week or more after chronic use.

Your Genetics Can Speed Things Up or Slow Things Down

Tamoxifen is not the main active agent in your body. The liver enzyme CYP2D6 converts it into endoxifen, which does most of the actual work of blocking estrogen receptors on breast cancer cells. The CYP2D6 gene is highly variable across individuals: some people carry two fully functional copies, some carry one working copy and one reduced-function copy, and some carry variants that produce little or no enzyme at all.

These genetic differences have a real impact on how long tamoxifen’s active metabolites stick around and at what concentrations. People with two functional copies of CYP2D6 produce endoxifen efficiently and generally reach higher steady-state levels of it. Those who carry reduced-function variants have endoxifen levels that can be two-fold lower or more. A study of Asian breast cancer patients found that individuals with two copies of the common reduced-function CYP2D6*10 allele had endoxifen concentrations roughly 2.4 to 2.6 times lower than those with two normal alleles.⁶ Similar findings have been reported in other populations.⁷

For clearance specifically, the picture is somewhat counterintuitive. If your CYP2D6 enzyme is slow or absent, you convert less tamoxifen into endoxifen, which means you may accumulate more of the parent drug and its less-active metabolites. Those compounds still need to be cleared. Whether poor metabolizers actually take longer to get tamoxifen fully out of their system has not been studied as directly as steady-state levels, but the altered metabolic profile means the mix of compounds lingering after discontinuation will be different, and the timeline for full clearance could shift in either direction depending on which metabolites dominate.

The clinical stakes are real. In patients with metastatic breast cancer, poor CYP2D6 metabolizers had significantly shorter overall survival compared to extensive metabolizers.⁸ This finding has driven interest in genotype-guided prescribing, though clinical guidelines have gone back and forth on whether routine CYP2D6 testing should be standard before starting tamoxifen.

Age Makes a Bigger Difference Than You Would Guess

Older women accumulate higher levels of tamoxifen and its metabolites than younger women on the same dose, and that means they likely take longer to fully clear the drug. One study found that women under 40 had a median combined tamoxifen-plus-metabolite concentration of about 802 nmol/L, while women over 80 had concentrations around 2,428 nmol/L, roughly three times higher.⁹ Another study confirmed that age was positively associated with higher plasma concentrations of tamoxifen and its main metabolite, even after adjusting for other factors.¹⁰

The reasons probably include age-related changes in body composition (more fat tissue to serve as a reservoir), slower liver metabolism, and reduced blood flow to the organs that clear the drug. Interestingly, liver dysfunction on its own did not have an obvious effect on drug concentrations in the first study, with the exception of a slight reduction in the proportion of parent tamoxifen relative to metabolites.⁹ So even if your liver is broadly healthy, age itself seems to be the stronger factor in how much drug builds up and, by extension, how long the tail of clearance takes.

Medications That Interfere With Clearance

Certain drugs, particularly some antidepressants, can substantially slow the conversion of tamoxifen to endoxifen by blocking the CYP2D6 enzyme. This does not just affect how well tamoxifen works against cancer; it also changes the metabolite profile that your body has to clear after discontinuation.

Paroxetine, an SSRI antidepressant, is the most studied offender. In a clinical trial, women who took paroxetine alongside tamoxifen saw their endoxifen levels drop by about 64 percent if they had normal CYP2D6 genes.¹¹ Laboratory work using humanized mouse models confirmed that SSRIs as a class are potent inhibitors of the enzyme pathway that generates endoxifen, with paroxetine among the strongest.¹² The concern goes beyond pharmacokinetics: co-administration of CYP2D6 inhibitors was associated with worse overall survival and shorter time to disease progression in patients with metastatic breast cancer.⁸

Not all SSRIs seem equally problematic in terms of cancer outcomes, though. A large observational study found that women who used citalopram or other SSRIs while on tamoxifen did not have a significantly increased rate of breast cancer recurrence.¹³ This may reflect differing potency against CYP2D6 across individual SSRI drugs. If you are taking an antidepressant alongside tamoxifen and are planning to stop tamoxifen, the interaction may affect how quickly the active metabolite profile normalizes, but the bigger clinical question is usually whether the antidepressant was undermining the drug’s effectiveness while you were on it.

Why Surgeons Want You to Stop Weeks Before an Operation

One of the main practical reasons people want to know how long tamoxifen lingers is perioperative planning. Tamoxifen increases the risk of venous thromboembolism (blood clots in the legs or lungs), and surgery on its own also raises that risk, so the combination is concerning. Published algorithms for managing tamoxifen around surgery typically recommend stopping the drug two to four weeks before an elective procedure, based on the pharmacokinetic data that roughly 98 percent of the drug is eliminated from plasma within about three weeks.¹

This timeline is not arbitrary. A three-week washout allows roughly two to three full half-lives to pass, which drops circulating levels enough that the excess clotting risk diminishes substantially. Some guidelines use a more conservative four-week window to account for individual variation in clearance. If your surgery is urgent rather than elective, the clot risk from tamoxifen has to be weighed against the risk of delaying the operation, and your surgical team may use anticoagulant prophylaxis instead of waiting for the drug to clear. After surgery, tamoxifen is generally restarted once you are up and moving and the acute clot-risk window has passed, though the exact timing varies by institution.

What About Tamoxifen’s Side Effects After Stopping?

Some women report that side effects like hot flashes, joint stiffness, or mood changes persist for weeks or even months after they stop tamoxifen. Part of this is explained by the slow clearance, since the drug and its metabolites are still circulating for several weeks. But some symptoms seem to outlast the drug itself. Hot flashes, for instance, may persist because the body’s thermoregulatory system takes time to recalibrate after years of estrogen-receptor blockade. The receptors tamoxifen was sitting on do not instantly return to normal signaling the moment blood levels hit zero.

If you are stopping tamoxifen because your prescribed course is complete (typically five to ten years of adjuvant therapy), you might also notice changes in menstrual patterns if you are premenopausal, or changes in vaginal dryness and bone density markers over the following months. These shifts reflect your body’s estrogen-receptor system reactivating, not residual drug. The timeline for those downstream effects varies widely and is separate from the pharmacokinetic question of when the drug itself is gone.

How Tamoxifen Shows Up on Drug Tests

Tamoxifen is banned by the World Anti-Doping Agency because it can be misused as an anti-estrogen in sports contexts. If you are subject to anti-doping testing, the detection window depends on the test methodology and the specific metabolite being targeted. One study using gas chromatography–mass spectrometry found that a particular tamoxifen metabolite was detectable in urine for up to five days after a single oral dose.⁴ That five-day window is for a single dose. After months or years of daily use, urine metabolites would persist longer because of the tissue stores feeding a slow trickle back into circulation. Blood-based testing can detect tamoxifen for the full three-week clearance window and potentially beyond, since metabolite fragments in trace amounts may linger even after the parent drug is functionally gone.

Standard clinical blood work does not routinely test for tamoxifen levels, though specialized assays exist and are sometimes used in research settings or to check whether a patient is adhering to therapy. If you are stopping tamoxifen and need documentation of clearance for any reason, your oncologist can order a plasma tamoxifen and endoxifen level, though turnaround times for these assays vary.

When Switching to a Different Hormone Therapy

Many breast cancer treatment plans involve switching from tamoxifen to an aromatase inhibitor after two to five years. The transition does not always include a washout period. In major clinical trials studying the switch from tamoxifen to anastrozole, patients moved directly from one drug to the other after completing their tamoxifen course, without a mandated gap.¹⁴ This suggests that overlapping the tail end of tamoxifen clearance with the beginning of aromatase inhibitor therapy is considered safe, and oncologists generally do not ask patients to wait three weeks for tamoxifen to clear before starting the new medication.

The reasoning is straightforward: both drugs are suppressing estrogen signaling, just through different mechanisms. Tamoxifen blocks the estrogen receptor directly, while aromatase inhibitors prevent estrogen from being made in the first place. Having both at work briefly as tamoxifen fades out is not harmful and avoids a gap in anti-cancer coverage. If you are switching and wondering whether you need a buffer period, in most cases the answer is no, but confirm with your oncologist, because individual situations sometimes call for a different approach.

1
International Journal of Surgery. Stopping tamoxifen peri-operatively for VTE risk reduction: A proposed management algorithm
2
PubMed. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data
3
PubMed Central. Population Pharmacokinetic Modelling to Assess the Impact of CYP2D6 and CYP3A Metabolic Phenotypes on the Pharmacokinetics of Tamoxifen and Endoxifen
4
Journal of Drug Delivery and Therapeutics. URINE EXCRETION STUDY OF TAMOXIFEN METABOLITE, 3-HYDROXY-4-METHOHY TAMOXIFEN BY GC-MS
5
PubMed. Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression
6
PubMed Central. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
7
PubMed Central. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
8
British Journal of Cancer. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
9
PubMed. Age-related difference in tamoxifen disposition
10
PubMed. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients
11
JNCI: Journal of the National Cancer Institute. Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
12
Drug Metabolism and Disposition. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug–Drug Interaction with Antidepressants
13
PubMed Central. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
14
The Lancet. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen